SCHEMBL4335625

SCHEMBL4335625

COc1cc(-c2noc(N)c2-c2ccncc2)ccc1F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 5/20 0.61
PAX8 Q06710 1/20 0.54
MLYCD O95822 2/20 0.50
MAPK9 P45984 2/20 0.44
MAPK10 P53779 2/20 0.44
MAPK11 Q15759 2/20 0.44
MEN1 O00255 1/20 0.44
GAA P10253 1/20 0.44
KMT2A Q03164 1/20 0.44
NPC1 O15118 1/20 0.42
MAPT P10636 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CSNK1D P48730 1/20 0.42
HSP90AA1 P07900 1/20 0.42
CA4 P22748 1/20 0.41
S1PR1 P21453 2/20 0.41
MAPK13 O15264 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4330105 0.88 MAPK14 (0.58) MAPK14MLYCDMAPK9MAPK10MAPK11
SCHEMBL4342443 0.84 MAPK14 (0.71) MAPK14MLYCDMAPK9MAPK10MAPK11
SCHEMBL4346693 0.84 MAPK14 (0.56) MAPK14PAX8MLYCDMAPK9MAPK10
SCHEMBL4337126 0.83 MAPK14 (0.66) MAPK14PAX8MLYCDMAPK9MAPK10
SCHEMBL4334530 0.81 MAPK14 (0.66) MAPK14MLYCDMAPK9MAPK10MAPK11
SCHEMBL4329365 0.81 MAPK14 (0.66) MAPK14MLYCDMAPK9MAPK10MAPK11
SCHEMBL4329246 0.81 MAPK14 (0.66) MAPK14MLYCDMAPK9MAPK10MAPK11
SCHEMBL4334590 0.80 MAPK14 (0.68) MAPK14MLYCDMAPK9MAPK10MAPK11
SCHEMBL4337249 0.79 MAPK14 (0.67) MAPK14MLYCDNPC1HSP90AA1SRC
SCHEMBL27765848 0.79 MAPK14 (0.63) MAPK14MLYCDMAPK9MAPK10MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207203-B2 Pyridylisoxazole derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-06-26 US disclosed
US-20090306145-A1 Pyridylisoxazole Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2036905-A1 PYRIDYLISOXAZOLE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2009-03-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306145-A1 Pyridylisoxazole Derivatives CNKSR1, MAPK1, MAPK3 MAPK14 43/4885PAX8 3847/4885MLYCD 4475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.